Gastrointestinal Cancer | Specialty

Dr. Richards on Using PARP Inhibitors in Metastatic Pancreatic Cancer

September 23rd 2019

Donald A. Richards, MD, PhD, discusses the potential benefits of PARP inhibitors in patients with metastatic pancreatic cancer who harbor somatic mutations.

FDA Approves CRC Screening Test for Younger, At-Risk Individuals

September 23rd 2019

The FDA has expanded the approval of the noninvasive colorectal cancer (CRC) screening test Cologuard to include eligible at-risk individuals ≥45 years.

Dr. Richards on the Phase III POLO Trial in BRCA-Mutated Pancreatic Cancer

September 21st 2019

Donald A. Richards, MD, PhD, medical oncologist, Texas Oncology, discusses the design and findings of the phase III POLO trial in patients with pancreatic cancer.

Experts Dissect Key Findings for Progressive Gastric and GEJ Cancers

September 20th 2019

Although chemotherapy combinations remain standard first-line therapy for advanced or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) cancer, strategies for progressive disease have shifted to include antiangiogenic agents and immunotherapy.

Top GI Oncologists Share Excitement on 16th Annual ISGIO Conference

September 20th 2019

Gastrointestinal oncology experts highlight what they are most excited for at the upcoming International Society of Gastrointestinal Oncology 16th Annual Gastrointestinal Oncology Conference.

Dr. Cohen on Eligibility for Ablation Therapy in Liver Cancer

September 19th 2019

Emil Israel Cohen, MD, an assistant professor at Medstar Georgetown University Hospital, discusses the criteria for ablation therapy in patients with liver cancer.

Dr. Richards on PARP Inhibition in Pancreatic Cancer

September 19th 2019

Donald A. Richards, MD, PhD, medical oncologist, Texas Oncology, discusses PARP inhibition in patients with pancreatic cancer.

Subset of BRAF non-V600-Mutant mCRC Is Potentially More Sensitive to Anti-EGFR Therapy

September 18th 2019

Patients with metastatic colorectal cancer who harbored BRAF non-V600, RAS-dependent mutations were more likely to respond to anti-EGFR therapy versus those with BRAF non-V600, RAS-independent mutations.

Dr. Manji on Treatment for NTRK Fusion+ CRC

September 18th 2019

Gulam A. Manji, MD, PhD, discusses treatment for patients with colorectal cancer who harbor NTRK fusions.

ISGIO Presents 16th Annual Gastrointestinal Oncology Conference

September 17th 2019

The International Society of Gastrointestinal Oncology, a not-for-profit global educational organization committed to gastrointestinal oncology, will host the 16th Annual Gastrointestinal Oncology Conference from Oct. 10-11, 2019 at the Hilton Crystal City in Arlington, Virginia.

Key Takeaway 8: MSI-High Status and HER2 Amplification

September 16th 2019

Key Takeaway 7: Role of Immunotherapy in MSI-High MCRC

September 16th 2019

Key Takeaway 6: I/O: Combination vs Monotherapy

September 16th 2019

Key Takeaway 5: Dosing of Multiple Kinase Inhibitors

September 16th 2019

Key Takeaway 4: Right-Sided Tumors: Anti-Angiogenic Treatment

September 16th 2019

Key Takeaway 3: Determining Tumor Mutational Status

September 16th 2019

Key Takeaway 2: Frontline Neoadjuvant Chemotherapy

September 16th 2019

Key Takeaway 1: Adjuvant Therapy Optimal Duration

September 16th 2019

Dr. Lieu Discusses the Focus of Future Research in mCRC

September 12th 2019

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses where future research should focus in metastatic colorectal cancer.

Gaining Ground in GI Cancers in Denver

September 11th 2019

We traveled to Denver, Colorado, for a State of the Science Summit™ on Gastrointestinal Cancers, which featured insights from University of Colorado and Rocky Mountain Cancer Centers faculty.